IntravenousAcute myocardial infarctionAdult: 10 units via slow inj over 2 minutes, immediately after onset of symptoms, followed by second dose, 30 minutes later.
|
|
|
|
|
Reconstitute vial labelled as containing 10 U with 10 mL of sterile water for inj.
|
Incompatible with heparin.
|
Active intracranial bleeding, history of cerebrovascular accident, recent or within 2 months of intracranial/intraspinal surgery or trauma, arteriovenous malformations or aneurysm, known bleeding diathesis, severe uncontrolled hypertension, within 3 months of ischemic stroke or significant closed head or facial trauma, active bleeding, suspected aortic dissection, active peptic ulceration, acute pancreatitis, pericarditis, bacterial endocarditis. Severe renal and hepatic impairment. Concomitant use with anticoagulants.
|
Patient with conditions that increase bleeding risk, MI. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
|
Significant: Arrhythmias, bleeding. Rarely, anaphylaxis.
Cardiac disorders: Recurrent ischaemia/angina, hypotension, heart failure, pulmonary oedema.
Gastrointestinal disorders: Gastrointestinal bleeding.
General disorders and administration site conditions: Inj site bleeding/haematoma, inj site reactions (e.g. burning sensation).
|
|
|
Monitor for signs of bleeding (e.g. haematuria, gastrointestinal, or gingival bleeding); CBC, prothrombin time, ECG.
|
Potentially Fatal: Increased risk of haemorrhage with anticoagulants (e.g. warfarin).
|
May alter coagulation and fibrinolytic activity test results.
|
Description: Reteplase is a nonglycosylated plasminogen activator (tPA) and proteolytic enzyme produced using E. coli recombinant DNA. It that converts plasminogen to plasmin, which in turn degrades the fibrin, thereby exerting its thrombolytic action.
Onset: Thrombolysis: 30-90 minutes.
Pharmacokinetics:
Excretion: Via faeces and urine. Elimination half-life: 13-16 minutes. Initial half-life: 14 minutes. Terminal half-life: Approx 1.6 hours (patients with MI).
|
Store between 2-25°C. Protect from light.
|
|
|
B01AD07 - reteplase ; Belongs to the class of enzymes. Used in the treatment of thrombosis.
|
Anon. Reteplase. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Buckingham R (ed). Reteplase. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Retavase (Chiesi USA, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/.
|
Sign Out
